Pharmaceutical company Amylin Pharmaceuticals, who sell diabetes drug Byetta, are going to let around 200 jobs go. The redundancies comprise approximately a third of the sales force of the company .
Alongside Eli Lilly, Amylin are developing a once-per-week version of diabetes drug Byetta. The aim of the restructuring is to strengthen the sales efficiency and the partnership with Lilly.
Amylin are thought to be seeking a final sales team of 325 representatives. The team will focus on doctors and endocrinologists who treat large number of people with diabetes .
The diabetes company, who largely specialise in drug for people with type 2 diabetes, will aim to save millions through the changes in the next few years.
Diabetes company to cut 200 jobs
Tue, 05 May 2009
Recommended links
Diabetes newsletterDiabetes and finance
Diabetes forum
Diabetes donate
Diabetes drug fails in study
Drug could also prevent diabetes
Risk of diabetes death cut by cheap pill
Whole grains cut diabetes risk
Chromium cuts weight gain in diabetes
New Lilly drug cuts diabetes vision loss risk
Cutting diabetes risk through exercise
Diabetes risk cut by vitamin D
Diabetes drug fears prompt job cuts
Diabetes and obesity will cut life span
Diabetes risk cut by blood pressure drug
Join us